# Patients' experiences of lung cancer

Insights from Spain

## Introduction

The Global Lung Cancer Coalition (GLCC), an alliance of 41 patient organisations from 29 countries across the world, wanted to understand the challenges patients are currently facing, to inform its patient advocacy work and the work of its member organisations.

In March 2024, the GLCC commissioned Censuswide to conduct a survey of lung cancer patients.

The survey received **905 responses** from patients across **18 countries**. For more information about the global findings, please visit www.lungcancercoalition.org/surveys.

# Key findings from Spain

**Demographics** 













lung cancer patients responded

80% identified as male;20% as female

53% had non-small cell lung cancer

were diagnosed in the last **five years** 

### **Experiences of biomarker testing**

All eligible respondents had been spoken to about biomarker testing



32% did not understand what biomarker testing was when they were first spoken to about it

These findings suggest a need for **improved communication around the topic of biomarker testing**.

#### Support preferences in coping with lung cancer

78% get help from healthcare professionals; 73% from family and friends;
20% from in-person support groups



27% would like to get help through counselling/therapy, but only 18% reported getting help that way

Respondents sought help from a variety of places. While their **preferences largely matched where they were already getting help,** respondents had a **greater desire for counselling/therapy** and **online-support groups**.

#### **Involvement with treatment teams**

#### **Preferred methods of receiving information**

**98%** of respondents said that they felt **involved** in decisions about their treatment and care



31% of respondents felt fully involved, but 61% wanted to be more involved Throughout the patient journey, **face-to-face interactions** were preferred in all situations



Print materials were

the most popular format for receiving information (preferred by 27%), followed by cancer support hotlines (24%)

While patient involvement was high, treatment teams need to ensure patients have the opportunity to be involved in decision-making as much as they would like to be. Whilst the results broadly indicate a preference for direct interaction when receiving information, it remains crucial that treatment teams understand and accommodate individual patient preferences.

# **Call to action**

This year's Patient Experience Survey highlighted **encouraging trends, including improved involvement in treatment and care decisions** when compared to last year's results. The results, however, also showed that more needs to be done to ensure all patients feel as involved as they would like in decision-making, that treatment teams clearly communicate to patients on topics relevant to their condition, such as biomarker testing, and that patients can access the support options of their preference.

The GLCC is therefore calling for the **implementation of the rights set out in its Patient Charter in Spain**, to ensure that all lung cancer patients have access to quality healthcare; informed self-determination, which includes involvement in decision-making; and physical and mental integrity.

## More information

The GLCC member in Spain is:

 Asociación Española de Afectados de Cáncer de Pulmón: www.afectadoscancerdepulmon.com



For more information about this survey and the work of the GLCC, please visit our website: https://www.lungcancercoalition.org/ or email our secretariat at: glcc@roycastle.org